CN110036025B - 变体ActRIIB蛋白及其用途 - Google Patents

变体ActRIIB蛋白及其用途 Download PDF

Info

Publication number
CN110036025B
CN110036025B CN201780074935.6A CN201780074935A CN110036025B CN 110036025 B CN110036025 B CN 110036025B CN 201780074935 A CN201780074935 A CN 201780074935A CN 110036025 B CN110036025 B CN 110036025B
Authority
CN
China
Prior art keywords
seq
polypeptide
actriib
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780074935.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110036025A (zh
Inventor
R·库马尔
A·格林伯格
E·M·沃根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CN110036025A publication Critical patent/CN110036025A/zh
Application granted granted Critical
Publication of CN110036025B publication Critical patent/CN110036025B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780074935.6A 2016-10-05 2017-10-05 变体ActRIIB蛋白及其用途 Active CN110036025B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404718P 2016-10-05 2016-10-05
US62/404,718 2016-10-05
PCT/US2017/055421 WO2018067874A1 (en) 2016-10-05 2017-10-05 Variant actriib proteins and uses thereof

Publications (2)

Publication Number Publication Date
CN110036025A CN110036025A (zh) 2019-07-19
CN110036025B true CN110036025B (zh) 2024-03-22

Family

ID=61831930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780074935.6A Active CN110036025B (zh) 2016-10-05 2017-10-05 变体ActRIIB蛋白及其用途

Country Status (10)

Country Link
US (2) US11267865B2 (enExample)
EP (1) EP3523328A4 (enExample)
JP (2) JP7280182B2 (enExample)
KR (2) KR102761094B1 (enExample)
CN (1) CN110036025B (enExample)
AU (3) AU2017338916B2 (enExample)
BR (1) BR112019006918A2 (enExample)
CA (1) CA3039525A1 (enExample)
MA (1) MA46471A (enExample)
WO (1) WO2018067874A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
EP3523328A4 (en) 2016-10-05 2020-04-01 Acceleron Pharma Inc. VARIANT ACTRIIB PROTEINS AND USES THEREOF
JOP20190085A1 (ar) * 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089706A2 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2019094751A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CA3099527A1 (en) 2018-05-03 2019-11-07 Acceleron Pharma Inc. Multispecific binders of tgf.beta.-superfamily ligands and uses thereof
US12168683B2 (en) 2018-05-03 2024-12-17 Acceleron Pharma Inc. Binders of TGFβ-superfamily ligands and uses thereof
AU2019266314B2 (en) * 2018-05-09 2025-05-15 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
AU2019285299A1 (en) * 2018-06-15 2020-12-03 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof
CN109293763B (zh) * 2018-10-26 2021-10-26 中国农业科学院特产研究所 水貂激活素b蛋白及其制备与应用
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
BR112022015387A2 (pt) * 2020-02-03 2022-10-11 Acceleron Pharma Inc Proteínas actriib variantes e usos das mesmas
WO2021189010A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2021263128A1 (en) * 2020-06-25 2021-12-30 Gliknik Inc. Ace2-fc fusion proteins and methods of use
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4274600A4 (en) * 2021-01-08 2024-11-20 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION
KR20240150761A (ko) 2022-01-28 2024-10-16 35파마 인크. 액티빈 수용체 유형 iib 변이체 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102656187A (zh) * 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
WO2015143403A1 (en) * 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
WO2015161220A1 (en) * 2014-04-18 2015-10-22 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
WO2015192111A1 (en) * 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
CN105884880A (zh) * 2007-02-02 2016-08-24 阿塞勒隆制药公司 由actriib衍生的变体及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
DE3588058T3 (de) 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US20050186593A1 (en) 1991-05-10 2005-08-25 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
ATE322681T1 (de) 1999-01-21 2006-04-15 Metamorphix Inc Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
UA116871C2 (uk) 2006-12-18 2018-05-25 Акселерон Фарма Інк. СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
KR20110031908A (ko) 2008-05-02 2011-03-29 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
EP2318028B1 (en) 2008-06-26 2020-02-19 Acceleron Pharma Inc. Antagonists of soluble activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
WO2010083034A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
KR101805201B1 (ko) 2009-03-30 2017-12-05 악셀레론 파마 인코포레이티드 Ｂｍｐ-ａｌｋ3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도
ES2844123T3 (es) * 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
MX340451B (es) * 2009-09-09 2016-07-08 Acceleron Pharma Inc Antagonistas de actriib y dosificacion y usos de los mismos.
JP6091894B2 (ja) 2009-09-16 2017-03-15 ジェネンテック， インコーポレイテッド コイルドコイルおよび／またはテザー含有タンパク質複合体およびその使用
WO2012027065A2 (en) 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
CN107837390A (zh) 2011-10-17 2018-03-27 阿塞勒隆制药公司 用于治疗无效性红细胞生成的方法和组合物
WO2013063536A1 (en) 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MA53400A (fr) 2015-04-06 2021-08-04 Acceleron Pharma Inc Hétéromultimères alk7: actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
EP3344660B1 (en) 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
CA3029890A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
EP3523328A4 (en) 2016-10-05 2020-04-01 Acceleron Pharma Inc. VARIANT ACTRIIB PROTEINS AND USES THEREOF
AU2017338921A1 (en) 2016-10-05 2019-04-18 Acceleron Pharma Inc. ALK4:ActRIIB heteromultimers and uses thereof
JP7097354B2 (ja) 2016-10-05 2022-07-07 アクセルロン ファーマ インコーポレイテッド Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089706A2 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105884880A (zh) * 2007-02-02 2016-08-24 阿塞勒隆制药公司 由actriib衍生的变体及其用途
CN105906707A (zh) * 2007-02-02 2016-08-31 阿塞勒隆制药公司 由actriib衍生的变体及其用途
CN105906708A (zh) * 2007-02-02 2016-08-31 阿塞勒隆制药公司 由actriib衍生的变体及其用途
CN105924517A (zh) * 2007-02-02 2016-09-07 阿塞勒隆制药公司 由actriib衍生的变体及其用途
CN102656187A (zh) * 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
WO2015143403A1 (en) * 2014-03-21 2015-09-24 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin b and/or gdf11
WO2015161220A1 (en) * 2014-04-18 2015-10-22 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
WO2015192111A1 (en) * 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
activin receptor type IIB [Homo sapiens];GenBank: BAA24180.2;NCBI;1-4 *
Blockade of ActRIIB Signaling Triggers Muscle Fatigability and Metabolic Myopathy;Karima Relizani等;《The American Society of Gene & Cell Therapy》;20140831;第22卷(第8期);第1423-1433页 *
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival;Xiaolan Zhou等;《CELL》;20100831;第4卷(第142期);第531-543页 *
脊髓性肌萎缩的诊疗进展;刘倩等;中国产前诊断杂志;第6卷(第3期);54-58 *

Also Published As

Publication number Publication date
EP3523328A1 (en) 2019-08-14
WO2018067874A1 (en) 2018-04-12
US20200055919A1 (en) 2020-02-20
AU2022201698A1 (en) 2022-04-07
JP2023033573A (ja) 2023-03-10
KR102595559B1 (ko) 2023-10-30
JP7617962B2 (ja) 2025-01-20
AU2017338916A1 (en) 2019-04-18
KR20230152811A (ko) 2023-11-03
AU2024200684A1 (en) 2024-02-22
KR20190073414A (ko) 2019-06-26
CA3039525A1 (en) 2018-04-12
BR112019006918A2 (pt) 2019-06-25
MA46471A (fr) 2021-05-19
AU2017338916B2 (en) 2022-03-24
US20220306724A1 (en) 2022-09-29
CN110036025A (zh) 2019-07-19
JP2019536440A (ja) 2019-12-19
KR102761094B1 (ko) 2025-02-03
JP7280182B2 (ja) 2023-05-23
US12240887B2 (en) 2025-03-04
US11267865B2 (en) 2022-03-08
EP3523328A4 (en) 2020-04-01

Similar Documents

Publication Publication Date Title
JP7617962B2 (ja) バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP7203807B2 (ja) シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7037363B2 (ja) Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用
EP2805967B1 (en) Variants derived from ActRIIB and uses therefor
JP7504947B2 (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP7159148B2 (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
JPWO2018009624A5 (enExample)
HK40057061A (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK40011178A (zh) 变体actriib蛋白及其用途
EP3735418A1 (en) Single-arm co-receptor fusion proteins and uses thereof
HK1252958B (zh) 单臂i型和ii型受体融合蛋白和其用途
HK1248732B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK1228413B (zh) 由actriib衍生的变体及其用途
HK1228411B (zh) 由actriib衍生的变体及其用途
HK1186477B (en) Variants derived from actriib and uses therefor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011178

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment